REDWOOD CITY, Calif. -- (Business Wire)
Vantage Health Inc., (OTCQB:VNTH) ("Vantage Health") or (the "Company")
today announced the appointment of Steven R. Steinhubl, M.D. as chairman
of the board. Dr. Steinhubl replaces interim chairman, Dr. Kevin Buckman
who will remain with the company in an advisory capacity.
Dr. Steinhubl is director of digital medicine at the Scripps
Translational Science Institute, and a practicing cardiologist at the
integrated Scripps Health system, both in San Diego. Dr. Steinhubl is
working to lead the clinical transformation of healthcare by enabling
the evidence driven adoption of mobile health technologies through the
design and management of pragmatic clinical trials.
Before joining Scripps Health, Dr. Steinhubl, a cardiologist, clinical
researcher and former pharmaceutical company executive, served as
director of cardiovascular wellness and a clinician-scientist at the
Geisinger Health System based in Danville, PA.
Among his many accolades with over 25 years in medicine, Dr. Steinhubl
served in the U.S. Air Force from 1991-2002 as a staff internist in
Alaska and afterwards as a Lt. Colonel staff cardiologist, Lackland Air
Force Base, Texas. He has led many funded research projects and trials
in the areas of cardiovascular science. His copious works in medical
research and cardiology have been published over 400 abstracts,
peer-reviewed manuscripts and book chapters.
He held several academic positions, starting as an Assistant Professor
of Medicine from 1998-2008 at Wilford Hall Medical Center, Lackland Air
Force Base, TX, Associate Professor at University of North Carolina and
University of Kentucky, and now a Professor at Scripps Translational
Science Institute.
Dr. Steinhubl attended Purdue University earning a B.S. in Chemical
Engineering; Georgetown University with a M.S. in Physiology and
attended St Louis University School of Medicine where he graduated Cum
Laude in 1988. He continued post doctorate training in Internal Medicine
completing his internship and residency at David Grant Medical Center in
conjunction with University of California, Davis School of Medicine and
Fellowship training in Cardiology and Interventional Cardiology at the
Cleveland Clinic.
About Vantage Health Inc.
Vantage Health Inc. - a mobile health technology company - is developing
personalized and point-of-care screening using Apps based upon chemical
sensing residing within a Bluetooth device that works with any
smartphone. With its foundations in advanced nanotechnology, the
company’s first product, the Vantage Health Sensor, which is in
development, is the convergence of nano-electronics, bio-informatics,
and wireless technology to create the next generation mobile health
application. The first mobile App is expected to be for lung cancer
screening with additional mobile healthcare Apps in the planning stages.
The company has offices in Redwood City, CA and New York. For more
information, please visit http://www.vantagehealthinc.com
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve risks and uncertainties that could cause actual results to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Such
forward-looking statements include, among other things statements with
respect to our objectives and strategies to achieve those objectives, as
well as statements with respect to our beliefs, plans, expectations,
anticipations, estimates or intentions. Such forward-looking statements
may also include statements, among other things, concerning the
efficacy, safety and intended utilization of Vantage’s product
candidates, the conduct and results of future clinical trials, plans
regarding regulatory filings, future research and clinical trials and
plans regarding partnering activities. Factors that may cause actual
results to differ materially include, among others, the risk that
product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later clinical trials, trials may have difficulty
enrolling, Vantage may not obtain approval to market its product
candidates, or outside financing may not be available to meet capital
requirements. These forward-looking statements are based on our current
expectations. We caution that all forward-looking information is
inherently uncertain and actual results may differ materially from the
assumptions, estimates or expectations reflected or contained in the
forward-looking information, and that actual future performance will be
affected by a number of factors, including economic conditions,
technological change, regulatory change and competitive factors, many of
which are beyond our control. Therefore, future events and results may
vary significantly from what we currently foresee.
For a further list and description of the risks and uncertainties the
Company faces, please refer to the Company’s most recent Annual Report
on Form 10-K and other periodic and other filings Vantage files with the
Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are
made, and Vantage assumes no obligation to update any forward-looking
statements, whether as a result of new information, future events or
otherwise.
Contacts:
CSIR Group, LLC. for Vantage Health
Christine Petraglia,
212-386-7082
Source: Vantage Health Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.